 Arcturus Therapeutics Holdings Inc NASDAQ: ARCT has announced updated data Phase 12 booster trial of ARCT-154 and ARCT-165, its investigational, self-amplifying mRNA COVID-19 vaccine candidates targeting the variants of concern. Data from the Phase 12 booster trial show that both ARCT-154 and ARCT-165, when administered as low-dose 5 mcg boosters at least five months after Pfizer Incs NYSE: PFE - BioNTech SEs NASDAQ: BNTX Comirnaty immunization, demonstrated robust antibody responses. 